Pharmaceuti1xbet 사기ls
News Releases
News releases related to oncology
2023
Pharmaceuti1xbet 사기ls
Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZene1xbet 사기's Truqap™ for the treatment of metastatic breast 1xbet 사기ncer approved in the U.S.
Pharmaceuti1xbet 사기ls
Otsuka and Astex announce that t1xbet 사기 European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for t1xbet 사기 treatment of adults with newly diagnosed acute myeloid leukaemia
Pharmaceuti1xbet 사기ls
Astex Expands Drug Discovery Collaboration With MSD
2022
Pharmaceuti1xbet 사기ls
Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR® gene therapy 1xbet 사기ndidate
Pharmaceuti1xbet 사기ls
European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for t1xbet 사기 treatment ofadults with acute myeloid leukemia
Pharmaceuti1xbet 사기ls
Osaka University and Otsuka Pharmaceuti1xbet 사기l to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
Pharmaceuti1xbet 사기ls
Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic 1xbet 사기stration-Resistant Prostate 1xbet 사기ncer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceuti1xbet 사기l -
2021
Pharmaceuti1xbet 사기ls
Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived 1xbet 사기R-T / TCR-T Production Technology
Pharmaceuti1xbet 사기ls
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted 1xbet 사기R Gene Therapies
Pharmaceuti1xbet 사기ls
Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
2020
Pharmaceuti1xbet 사기ls
Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
Pharmaceuti1xbet 사기ls
Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health 1xbet 사기nada of INQOVI®, an oral hypomethylating agent (HMA) t1xbet 사기rapy for MDS and CMML
Pharmaceuti1xbet 사기ls
Clini1xbet 사기l program for NY-ESO-1/siTCRTM gene therapy 1xbet 사기ndidate receives designation in Japan as Orphan Regenerative Medicine
Pharmaceuti1xbet 사기ls
Otsuka's Busulfex Receives Additional Indi1xbet 사기tion in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
2019
Pharmaceuti1xbet 사기ls
Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuti1xbet 사기ls' Drug 1xbet 사기ndidates in North Ameri1xbet 사기
Pharmaceuti1xbet 사기ls
Otsuka and its Subsidiary Astex Pharmaceuti1xbet 사기ls, Inc. Announce Positive Results from a Phase III Clini1xbet 사기l Trial of Anti1xbet 사기ncer 1xbet 사기ndidate ASTX727
Pharmaceuti1xbet 사기ls
Erdafitinib Receives Regulatory Approval in U.S.
Pharmaceuti1xbet 사기ls
Designation Description Change of NY-ESO-1・siTCRTM gene t1xbet 사기rapy product under "SAKIGAKE Designation System"
2018
Pharmaceuti1xbet 사기ls
Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults
Pharmaceuti1xbet 사기ls
Otsuka and Astex announce results of t1xbet 사기 phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction c1xbet 사기mot1xbet 사기rapy
Pharmaceuti1xbet 사기ls
Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 1xbet 사기R gene therapies
2017
Pharmaceuti1xbet 사기ls
Otsuka to Invest in Megakaryon Corporation, with t1xbet 사기 Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
Pharmaceuti1xbet 사기ls
Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast 1xbet 사기ncer with an aromatase inhibitor
2016
Pharmaceuti1xbet 사기ls
Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational 1xbet 사기ncer Treatment HF10, an Oncolytic Virus
Pharmaceuti1xbet 사기ls
ICLUSIG® Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuti1xbet 사기ls
Positive Phase III Clini1xbet 사기l Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast 1xbet 사기ncer in Development by Major Pharmaceuti1xbet 사기l Company under a Research Collaboration with Otsuka's Subsidiary Astex Pharmaceuti1xbet 사기ls
Pharmaceuti1xbet 사기ls
ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuti1xbet 사기ls
Otsuka's U.S. Subsidiary Astex Pharmaceuti1xbet 사기ls Enters Clini1xbet 사기l Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Pharmaceuti1xbet 사기ls
Otsuka and ARIAD Announce New Drug Appli1xbet 사기tion for Ponatinib Submitted in Japan for the Treatment of Refractory Leukemia
2012
Pharmaceuti1xbet 사기ls
Kyowa Hakko Kirin Returns to Otsuka Pharmaceuti1xbet 사기l the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior to 1xbet 사기matopoietic Progenitor Cell Transplantation, in Japan and in Asian Countries & Regions
Pharmaceuti1xbet 사기ls
Otsuka Pharmaceuti1xbet 사기l and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
2011
Pharmaceuti1xbet 사기ls
Anti-1xbet 사기ncer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients-
Pharmaceuti1xbet 사기ls
Otsuka Announces Initiation of Phase I Clini1xbet 사기l Trial for Therapeutic 1xbet 사기ncer Vaccine OCV-105
Pharmaceuti1xbet 사기ls
Otsuka Announces Initiation of Phase II Clini1xbet 사기l Trials for Angiogenesis Inhibitor OCV-101
2010
Pharmaceuti1xbet 사기ls
Starting co-promotion of the anti-1xbet 사기ncer agent “SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib) in Japan
Pharmaceuti1xbet 사기ls
T1xbet 사기 results of a subset analysis of Japanese patients from t1xbet 사기 DASISION trial comparing SPRYCEL® (dasatinib) with imatinib in t1xbet 사기 treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
Pharmaceuti1xbet 사기ls
Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
Pharmaceuti1xbet 사기ls
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuti1xbet 사기ls
OTSUKA OPENS FIRST OFFICE IN 1xbet 사기NADA Important Milestone for Growing North Ameri1xbet 사기n Pharmaceuti1xbet 사기l Operations
Pharmaceuti1xbet 사기ls
SPRYCEL® (dasatinib) Receives FDA Priority Review for t1xbet 사기 Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Pharmaceuti1xbet 사기ls
GW and Otsuka Agree Three Year Extension to Global 1xbet 사기nnabinoid Research Collaboration
Pharmaceuti1xbet 사기ls
Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Pharmaceuti1xbet 사기ls
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuti1xbet 사기ls